PL348107A1 - Therapy for improving cognition - Google Patents
Therapy for improving cognitionInfo
- Publication number
- PL348107A1 PL348107A1 PL99348107A PL34810799A PL348107A1 PL 348107 A1 PL348107 A1 PL 348107A1 PL 99348107 A PL99348107 A PL 99348107A PL 34810799 A PL34810799 A PL 34810799A PL 348107 A1 PL348107 A1 PL 348107A1
- Authority
- PL
- Poland
- Prior art keywords
- therapy
- improving cognition
- cognition
- improving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98203454 | 1998-10-16 | ||
PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
Publication Number | Publication Date |
---|---|
PL348107A1 true PL348107A1 (en) | 2002-05-06 |
Family
ID=8234219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL99348107A PL348107A1 (en) | 1998-10-16 | 1999-10-12 | Therapy for improving cognition |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1121131A2 (ko) |
JP (1) | JP2002527469A (ko) |
KR (1) | KR20010072878A (ko) |
CN (1) | CN1367697A (ko) |
AU (1) | AU6472799A (ko) |
BG (1) | BG105302A (ko) |
BR (1) | BR9914419A (ko) |
CA (1) | CA2345767A1 (ko) |
EE (1) | EE200100136A (ko) |
HK (1) | HK1039745A1 (ko) |
HR (1) | HRP20010262A2 (ko) |
HU (1) | HUP0103781A3 (ko) |
ID (1) | ID28441A (ko) |
IL (1) | IL142588A0 (ko) |
NO (1) | NO20011403L (ko) |
PL (1) | PL348107A1 (ko) |
SK (1) | SK4592001A3 (ko) |
TR (1) | TR200101082T2 (ko) |
WO (1) | WO2000023057A2 (ko) |
ZA (1) | ZA200103081B (ko) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
CN1578664A (zh) | 2001-10-30 | 2005-02-09 | 诺瓦提斯公司 | 伊潘立酮和星状聚合物的贮库制剂 |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
CA2551486A1 (en) * | 2003-12-22 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
CA2552221A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
ATE183084T1 (de) * | 1991-05-14 | 1999-08-15 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
CA2300148C (en) * | 1997-08-11 | 2009-06-23 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
AU765603C (en) * | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
-
1999
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Application Discontinuation
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/no not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000023057A3 (en) | 2000-07-27 |
WO2000023057A2 (en) | 2000-04-27 |
AU6472799A (en) | 2000-05-08 |
EP1121131A2 (en) | 2001-08-08 |
JP2002527469A (ja) | 2002-08-27 |
IL142588A0 (en) | 2002-03-10 |
BG105302A (en) | 2001-11-30 |
SK4592001A3 (en) | 2001-12-03 |
EE200100136A (et) | 2002-06-17 |
HUP0103781A2 (hu) | 2002-03-28 |
HK1039745A1 (zh) | 2002-05-10 |
ID28441A (id) | 2001-05-24 |
NO20011403D0 (no) | 2001-03-20 |
KR20010072878A (ko) | 2001-07-31 |
TR200101082T2 (tr) | 2001-09-21 |
HRP20010262A2 (en) | 2002-06-30 |
CA2345767A1 (en) | 2000-04-27 |
ZA200103081B (en) | 2002-07-12 |
NO20011403L (no) | 2001-03-20 |
BR9914419A (pt) | 2001-06-26 |
HUP0103781A3 (en) | 2003-09-29 |
CN1367697A (zh) | 2002-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL348107A1 (en) | Therapy for improving cognition | |
AP2002002661A0 (en) | Combination therapy for oesteoporosis | |
GB9816263D0 (en) | Therapeutic agents | |
GB9806102D0 (en) | Therapeutic agents | |
EP1077704A4 (en) | COMBINATION THERAPY FOR TREATING DEPRESSION | |
GB9804885D0 (en) | Therapeutic combination | |
GB9808663D0 (en) | Therapeutic agents | |
GB9801234D0 (en) | Therapeutic agents | |
GB9813576D0 (en) | Therapeutic agents | |
GB9813006D0 (en) | Therapeutic agents | |
GB9801210D0 (en) | Therapeutic agents | |
GB9816556D0 (en) | Therapy | |
AP9901436A0 (en) | Therapeutic agents | |
GB9801397D0 (en) | Therapeutic agents | |
HUP0101947A3 (en) | Combination for the treatment of tumors | |
GB9801202D0 (en) | Therapeutic agents | |
GB9808665D0 (en) | Therapeutic compounds | |
GB9824897D0 (en) | Therapeutic compounds | |
GB9810092D0 (en) | Therapeutic agents | |
GB9811879D0 (en) | Therapeutic agents | |
GB9815317D0 (en) | Therapeutic agents | |
GB0020261D0 (en) | Therapeutic treatment | |
GB9817838D0 (en) | Therapeutic agents | |
GB9805716D0 (en) | Therapeutic agents | |
GB9808667D0 (en) | Therapeutic compounds |